Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients

Table 2 Hazard ratio (HR) of relapse of ER-positive postmenopausal breast cancer patients for median (0.403 ng/mL), third quartile (0.532 ng/mL) and 95% percentile (0.782 ng/mL) with respect to the first quartile (0.278 ng/mL) of testosterone levels, according to BMI groups

Testosterone^a level (ng/mL)	BMI < 25	BMI 25–30	BMI ≥30
Testosterone^a level (ng/mL)	HR^b (95% CI)	HR^b (95% CI)	HR^b (95% CI)
0.403 versus 0.278	5.52 (1.65–18.49)	1.64 (0.69–3.91)	0.68 (0.40–1.14)
0.532 versus 0.278	4.55 (1.09–18.98)	2.45 (0.75–8.02)	0.61 (0.31–1.20)
0.782 versus 0.278	0.25 (0.01–6.55)	4.68 (1.39–15.70)	0.75 (0.22–2.55)

^aTestosterone levels were included as a continuous variable into the model
^bTumour size and the number of metastatic lymph nodes were included in the Cox proportional hazard regression model as adjusting covariates. In parenthesis, pertinent 95% confidence interval

ISSN: 1471-2407